Inhaled drug therapy development for the treatment of migraine

References

• Ruge CA, Kirch J, Lehr C-M. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 2013 Jul;1(5):402–413.
   PubMed Web of Science ®Google Scholar
• Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care. 2010 Jul;55(7):911–921.
   PubMed Web of Science ®Google Scholar
• Murgia X, De Souza Carvalho C, Lehr C. Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. Eur J Nanomed. 2014;6(3):157–169.
   Google Scholar
• Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004 Nov;1(1):67–86.
   PubMedGoogle Scholar
• Levitzky MG. Chapter 1. Function and structure of the respiratory system. In: Levitzky MG, editor. Pulmonary physiology, 8e. New York (NY): McGraw-Hill; 2013.
   Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003 Dec;56(6):588–599.
   PubMed Web of Science ®Google Scholar
• Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19(1):3–36.
   Web of Science ®Google Scholar
• Rau JL. The inhalation of drugs: advantages and problems. Respir Care. 2005 Mar;50(3):367–382.
   PubMedGoogle Scholar
• Dolovich MD, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence based guidelines. Chest. 2005;127(1):335–371.
   PubMed Web of Science ®Google Scholar
• Meakin BJ, Cainey J, Woodcock PM. Effect of exposure to humidity on terbutaline delivery from turbohaler dry powder inhalation devices. Eur Respir J. 1993;6(5):760–761.
   PubMed Web of Science ®Google Scholar
• Noymer P, Biondi S, Myers D, et al. Pulmonary delivery of therapeutic compounds for treating CNS disorders. Ther Deliv. 2011;2(9):1125–1140.
   PubMedGoogle Scholar
• Kakade P, Cook R, Wang Y, et al. Advancing inhaler performance through airflow management. J Aerosol Med Pulm Drug Deliv. 2009 June;22(2):173–208.
   Google Scholar
• Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TempoTM) inhaler. Headache. 2008 Mar;48(3):355–367.
   PubMed Web of Science ®Google Scholar
• Longest PW, Hindle M, Das Chouduri S, et al. Developing a better understanding of spray system design using a combination of CFD modeling and experiment. Respiratory Drug Delivery. 2008;1:151–164.
   Google Scholar
• Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006 Winter;19(4):473–483.
   PubMedGoogle Scholar
• Staccato Platform Details. Alexza Pharmaceuticals. [cited 2015 Dec 17]. Available from: http://www.alexza.com/staccato/staccato-platform
   Google Scholar
• Gonda I. Systemic delivery of drugs to humans via inhalation. J Aerosol Med. 2006 Spring;19(1):47–53.
   PubMedGoogle Scholar
• Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci. 2013 Apr;102(4):1165–1172.
   PubMed Web of Science ®Google Scholar
• Headache Classification of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:627–808.
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015 Jan;55(1):21–34.
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Al Jumah M, Birbeck GL, et al. The methodology of population surveys of headache prevalence, burden and cost: principles and recommendations from the global campaign against headache. J Headache Pain. 2014;15:5.
   PubMed Web of Science ®Google Scholar
• Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009 May;84(5):436–445.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review) report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000 Sep 26;55(6):754–762.
   PubMed Web of Science ®Google Scholar
• Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs. 2001 Oct;10(10):1831–1845.
   PubMed Web of Science ®Google Scholar
• Schardl CL, Panaccione DG, Tudzynski P. Ergot alkaloids–biology and molecular biology. Alkaloids Chem Biol. 2006;63:45–86.
   PubMedGoogle Scholar
• Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013;53(S2):43–53.
   PubMed Web of Science ®Google Scholar
• Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry. 1938;39:737–763.
   Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144–166.
   PubMed Web of Science ®Google Scholar
• Stoll A, Hofmann A. Die alkaloide der erogtixingruppe: ergocristin, ergokryptin, ergocomine. Helv Chir Acta. 1943;25:1570–1601.
   Google Scholar
• Berde B, Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Shild HO, editors. Ergot alkaloids and related compounds. New York (NY): Springer-Verlag; 1978.
   Google Scholar
• Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc. 1945;20:241–248.
   Web of Science ®Google Scholar
• Scott AL. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neuropharmcol. 1992;15:289–296.
   PubMed Web of Science ®Google Scholar
• Winner P, Ricalde O, Leforce B, et al. A double-bind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53:180–184.
   PubMed Web of Science ®Google Scholar
• Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36(7):995–997.
   PubMed Web of Science ®Google Scholar
• Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010;50(8):1353–1361.
   PubMed Web of Science ®Google Scholar
• Dodick D, Lipton RB, Martin V, et al. Triptan cardiovascular safety expert panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–425.
   PubMed Web of Science ®Google Scholar
• Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006;13:1009–1013.
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997;49:201–206.
   PubMed Web of Science ®Google Scholar
• Jones J, Sklar D, Dougherty J, et al. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989;261:1174–1176.
   PubMed Web of Science ®Google Scholar
• Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med. 1998;5:573–576.
   PubMed Web of Science ®Google Scholar
• Ginder S, Oatman B, Pollack M. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J Emerg Med. 2000;18:311–315.
   PubMed Web of Science ®Google Scholar
• Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of acute migraine headache. Am J Emerg Med. 1996;14:262–264.
   PubMed Web of Science ®Google Scholar
• Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14(1):27–35.
   PubMed Web of Science ®Google Scholar
• Schiele BC. Loxapine succinate: a controlled double-blind study in chronic schizophrenia. Dis Nerv Syst. 1975;36(7):361–364.
   PubMedGoogle Scholar
• Mazzola CD, Miron S, Jenkins AJ. Loxapine intoxication: case report and literature review. J Anal Toxicol. 2000;24(7):638–641.
   PubMed Web of Science ®Google Scholar
• Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27(6):479–489.
   PubMed Web of Science ®Google Scholar
• Valdes J, Shipley T, Rey JA. Loxapine inhalation powder (Adasuve): a new and innovative formulation of an antipsychotic treatment for agitation. Pharm Ther. 2014;39(9):621–648.
   Google Scholar
• Gallagher R. What do patients want from acute migraine treatment? Cephalalgia. 2004;24(Suppl 2):8–15.
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about the side effects may delay treatment. Headache. 2003;243:36–43.
   Web of Science ®Google Scholar
• Little PJ, Jennings GL, Skews H, et al. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982;13:785–790.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Lipton RS. Dihydroergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. New York (NY): Raven Press; 1993. p. 313–322.
   Google Scholar
• Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447–453.
   PubMed Web of Science ®Google Scholar
• Aurora S, Kori S, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443–1446.
   PubMed Web of Science ®Google Scholar
• Nagy AJ, Rapoport AM. Update on future headache treatments. Neurol Sci. 2013;34(Suppl 1):S101–S108.
   Google Scholar
• Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012;13(13):1961–1968.
   PubMed Web of Science ®Google Scholar
• Shrewsbury SB, Kori SH, Miller SD, et al. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008;24:1977–1985.
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(Suppl 4):S171–S181.
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia. 1991;11(4):165–168.
   PubMed Web of Science ®Google Scholar
• Cook RO, Shewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009;49:1423–1434.
   PubMed Web of Science ®Google Scholar
• Kellerman DJ, Forst A, Combs DL, et al. Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies. J Aerosol Med Pulm Drug Deliv. 2013 Oct;26(5):297–306.
   PubMed Web of Science ®Google Scholar
• Forst A, Febbraro S, Kellerman D, et al. An open-lbel, two-period crossover study comparing the pharmacokinetics and tolerability of LEVADEXTM (MAP0004, orally inhaled DHE) and intravenous DHE (DHE45®) in smoking and non-smoking adult volunteers [Abstract]. Headache. 2011;51(Suppl 1):17.
   Google Scholar
• Dolovich M, Sanchis J, Rossman C, et al. Aerosol penetrance: a sensitive index of periheral airways obstruction. J Appl Physiol. 1976;40:468–471.
   PubMed Web of Science ®Google Scholar
• Dalby C, Polanowski T, Larsson T, et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.
   PubMed Web of Science ®Google Scholar
• Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia. 2011;31:43–64.
   PubMed Web of Science ®Google Scholar
• Muller-Schweinitzer E. Pharmacologic actions of the main metabolits of dihydroergotamine. Eur J Clin Pharmacol. 1984;26:699–705.
   PubMed Web of Science ®Google Scholar
• Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984;12:463–470.
   Web of Science ®Google Scholar
• Copeland RA, Pompliano DL, Meek TD. Drug target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5:730–739.
   PubMed Web of Science ®Google Scholar
• Kori S, Zhang J, Kellerman D. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors [Abstract]. J Headache Pain. 2013;14(Suppl 1):P75.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49:826–837.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507–517.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Kori SH, Borland SW, et al. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012;52:37–47.
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26.
   PubMed Web of Science ®Google Scholar
• Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161:658–660.
   PubMed Web of Science ®Google Scholar
• Landy S, Rice K, Lobo B. Central sensitization and cutaneous allodynia in migraine: implications for treatment. CNS Drugs. 2004;18:337–342.
   PubMed Web of Science ®Google Scholar
• Pozo-Rosich P, Oshinsky ML. Effect of dihydroergotamine (DHE) on central sensitization of neurons in the trigeminal nucleus caudalis [abstract]. Neurology. 2005;64:A151.
   Google Scholar
• Silberstein SD, Young WB, Hopkins MM, et al. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache. 2007;47:878–885.
   PubMed Web of Science ®Google Scholar
• Kori S, Kellerman D, Chang J, et al. A long-term open-label study assessing the safety and tolerability of MAP0004 orally inhaled dihydroergotamine in adult migraineurs. 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); 2012 Feb 23-26; Palm Springs,CA. (Abstract).
   Google Scholar
• Noveck RJ, Douglas PS, Chow SC, et al. Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. Drug Des Devel Ther. 2013 Jul;24(7):619–625.
   Google Scholar
• Kori S 1, Kellerman DJ, Voloshko P, et al. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers. Clin Ther. 2012 Sep;34(9):1920–1928.
   PubMed Web of Science ®Google Scholar
• Leroy F, Asseman P, Pruvost P, et al. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med. 1988;109:249.
   PubMed Web of Science ®Google Scholar
• Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritnovir and ergotamine. Ann Intern Med. 1999;130:329–330.
   PubMed Web of Science ®Google Scholar
• Delaforge M, Rivire R, Sartori E, et al. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica. 1989;19:1285–1295.
   PubMed Web of Science ®Google Scholar
• Kellerman D, Kori S, Forst A, et al. Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans. Celphalalgia. 2001;32:150–15867.
   Web of Science ®Google Scholar
• Schuster NM, Vollbracht S, Rapoport AM. Emerging treatments for the primary headache disorders. Neurol Sci. 2015;36(Suppl 1):S109–S113.
   Google Scholar
• Avram MJ, Henthorn TK, Spyker DA, et al. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazineadministered as a thermally generated aerosol in a single breath to dogs. Drug Metab Dispos. 2007 Feb;35(2):262–267.
   PubMed Web of Science ®Google Scholar
• Avram MJ, Spyker DA, Henthorn TK, et al. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther. 2009;85:71–77.
   PubMed Web of Science ®Google Scholar
• Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiat. 1984;45:331–336.
   PubMed Web of Science ®Google Scholar
• Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991;32:677–684.
   PubMed Web of Science ®Google Scholar
• Cassella J, Spyker D, Skowronski R, et al. Novel inhalation technology delivers intravenous-like pharmacokinetics of prochlorperazine in healthy volunteers. Headache. 2005 June;45(6):805–823.
   Google Scholar
• Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci. 2006 Nov;95(11):2438–2451.
   PubMed Web of Science ®Google Scholar
• Taylor WB, Bateman DN. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987;23(2):137–142.
   PubMed Web of Science ®Google Scholar
• Cassella J, Spyker D, Mei L, et al. Inhaled prochlorperazine reduces headache pain in patients having an acute migraine attack. Headache. 2006 May;46(5):833–904.
   Google Scholar
• Alexza’s AZ-001 Phase IIb Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache. Alexz Press Release. [cited 2015 Dec 17]. Available from: http://5amventures.com/documents/news/032607%20Alexa’s%20AZ-001.pdf 104
   Google Scholar
• Prochlorperazine inhalation- Alexza Pharmacueticals. Adis Insight. [cited 2015 Dec 17]. Available from: http://webcache.googleusercontent.com/search?q=cache:qHqUUAODEv4J:adisinsight.springer.com/drugs/800021922+&cd=3&hl=en&ct=clnk&gl=us
   Google Scholar
• Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):169–179.
   PubMed Web of Science ®Google Scholar
• Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993;31:177–183.
   PubMed Web of Science ®Google Scholar
• Takahashi LH, Huie K, Spyker DA, et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit. 2014;36(5):618–623.
   PubMed Web of Science ®Google Scholar
• Loxapine low dose inhalation. Adis Insight. [cited 2015 Dec 17]. Available from: http://webcache.googleusercontent.com/search?q=cache:qrmCcMQS0FQJ:adisinsight.springer.com/drugs/800026488+&cd=1&hl=en&ct=clnk&gl=us
   Google Scholar
• Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache. [cited 2015 Dec 17]. Available from: http://www.fiercebiotech.com/press-releases/alexza-announces-preliminary-results-its-az-104-staccato-r-loxapine-phase-2b-trial–0
   Google Scholar
• Gross N, Greos LS, Meltzer EO, et al. Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease–two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014 Dec;27(6):478–487.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012 Sep;17(3):393–406. Epub 2012 Aug 3. doi:10.1517/14728214.2012.709846.
   PubMed Web of Science ®Google Scholar